RECURRENT
Clinical trials for RECURRENT explained in plain language.
Never miss a new study
Get alerted when new RECURRENT trials appear
Sign up with your email to follow new studies for RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to outsmart ALK lung cancer
Disease control OngoingThis study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…
Matched conditions: RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immune cells Re-Trained to fight Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial investigates whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be re-stimulated in the lab and infused back to fight platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Participants receive their r…
Matched conditions: RECURRENT
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC